Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies.

The transcription factor Yin Yang (YY) 1 has been reported to be overexpressed in several tumor types and plays a role in both the progression of the disease as well as the maintenance of tumor cell resistance to cell death by cytotoxic drugs. YY1 also has been reported to be a prognostic factor for several cancers and was proposed to be a therapeutic target. The expression, function, and role of YY1 in the pathogenesis of hematologic malignancies are summarized briefly herein. Data are represented for B non-Hodgkin lymphoma, AIDS-related lymphoma, multiple myeloma, and children's acute lymphocytic leukemia.

[1]  Giancarlo Castellano,et al.  The involvement of the transcription factor Yin Yang 1 in cancer development and progression , 2009, Cell cycle.

[2]  R. Wall,et al.  A conserved sequence upstream of the B29 (Igβ, CD79b) gene interacts with YY1 , 2004, Molecular Biology Reports.

[3]  Ruud Delwel,et al.  The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation. , 2003, Blood.

[4]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[5]  Adam A. Margolin,et al.  Reverse engineering of regulatory networks in human B cells , 2005, Nature Genetics.

[6]  S. Farahat,et al.  P-Glycoprotein (P-170) expression in acute leukemias , 2006, Hematology.

[7]  S. Grossman,et al.  Yin Yang 1 Is a Negative Regulator of p53 , 2004, Cell.

[8]  J. Ericsson,et al.  YY1 inhibits the activation of the p53 tumor suppressor in response to genotoxic stress. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Spandidos,et al.  Chemotherapeutic drugs sensitize cancer cells to TRAIL-mediated apoptosis: up-regulation of DR5 and inhibition of Yin Yang 1 , 2007, Molecular Cancer Therapeutics.

[10]  K. Offit,et al.  Intermediate- to high-grade histology of lymphomas carrying t(14;18) is associated with additional nonrandom chromosome changes. , 1987, Blood.

[11]  S. Saleque,et al.  Yin Yang 1 Is a Lipopolysaccharide-Inducible Activator of the Murine 3′ Igh Enhancer, hs3 1 , 2003, The Journal of Immunology.

[12]  Zhenqi Shi,et al.  YY1 is involved in RANKL-induced transcription of the tartrate-resistant acid phosphatase gene in osteoclast differentiation. , 2004, Gene.

[13]  J. Armitage,et al.  Symposium on Oncology Practice: Hematological Malignancies Non-hodgkin Lymphoma: Diagnosis and Treatment for Personal Use. Mass Reproduce Only with Permission from Mayo Clinic Proceedings. for Personal Use. Mass Reproduce Only with Permission from Mayo Clinic Proceedings. for Personal Use. Mass Repr , 2022 .

[14]  T. Sakai,et al.  Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. , 2009, Nitric oxide : biology and chemistry.

[15]  M. Oken,et al.  Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. , 1987, The New England journal of medicine.

[16]  I. Duncan,et al.  Maternal expression of genes that regulate the bithorax complex of Drosophila melanogaster. , 1986, Developmental biology.

[17]  B. Bonavida,et al.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology , 2006, Oncogene.

[18]  R. Terracciano,et al.  Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? , 2006, European journal of cancer.

[19]  K. Rajewsky,et al.  Yin Yang 1 is a critical regulator of B-cell development. , 2007, Genes & development.

[20]  S. Horvath,et al.  Expression of transcription factor Yin Yang 1 in prostate cancer. , 2005, International journal of oncology.

[21]  D. Spandidos,et al.  Overexpression of VEGF and TGF-beta1 mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: implication of YY1 in cervical tumorigenesis and HPV infection. , 2007, International journal of oncology.

[22]  Gideon Rechavi,et al.  Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. , 2005, Blood reviews.

[23]  S. Bicciato,et al.  Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Bonavida,et al.  Nitric oxide sensitizes ovarian tumor cells to Fas-induced apoptosis. , 1999, Gynecologic oncology.

[25]  Yang Shi,et al.  Targeted Disruption of Mouse Yin Yang 1 Transcription Factor Results in Peri-Implantation Lethality , 1999, Molecular and Cellular Biology.

[26]  B. Trock,et al.  Autoantibodies to the Nucleolar Phosphoprotein Nucleophosmin in Breast Cancer Patients , 1998 .

[27]  P. Gaulard,et al.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  B. Bonavida,et al.  Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis , 2005, Oncogene.

[29]  Yang Shi,et al.  Essential Dosage-Dependent Functions of the Transcription Factor Yin Yang 1 in Late Embryonic Development and Cell Cycle Progression , 2006, Molecular and Cellular Biology.

[30]  P. L. Bergsagel,et al.  Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. , 2008, The Journal of clinical investigation.

[31]  D J Anderson,et al.  The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes , 1995, Science.

[32]  R. Kimberly,et al.  A Promoter Haplotype of the Immunoreceptor Tyrosine-Based Inhibitory Motif-Bearing FcγRIIb Alters Receptor Expression and Associates with Autoimmunity. II. Differential Binding of GATA4 and Yin-Yang1 Transcription Factors and Correlated Receptor Expression and Function12 , 2004, The Journal of Immunology.

[33]  K. Tarte,et al.  Microarray‐based understanding of normal and malignant plasma cells , 2006, Immunological reviews.

[34]  Pascale Jackers,et al.  Yin Yang 1 Cooperates with Activator Protein 2 to Stimulate ERBB2 Gene Expression in Mammary Cancer Cells* , 2005, Journal of Biological Chemistry.

[35]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[36]  G. Martin,et al.  An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination , 1998, Nature Genetics.

[37]  B. Bonavida,et al.  Nitric Oxide Inhibits the Transcription Repressor Yin-Yang 1 Binding Activity at the Silencer Region of the Fas Promoter: A Pivotal Role for Nitric Oxide in the Up-Regulation of Fas Gene Expression in Human Tumor Cells1 , 2001, The Journal of Immunology.

[38]  K. Calame,et al.  Yin-yang 1 activates the c-myc promoter , 1993, Molecular and cellular biology.

[39]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[40]  E. Moran,et al.  Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. , 1995, Genes & development.